203 related articles for article (PubMed ID: 31217199)
1. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Frezza AM; Jones RL; Lo Vullo S; Asano N; Lucibello F; Ben-Ami E; Ratan R; Teterycz P; Boye K; Brahmi M; Palmerini E; Fedenko A; Vincenzi B; Brunello A; Desar IME; Benjamin RS; Blay JY; Broto JM; Casali PG; Gelderblom H; Grignani G; Gronchi A; Hall KS; Mir O; Rutkowski P; Wagner AJ; Anurova O; Collini P; Dei Tos AP; Flucke U; Hornick JL; Lobmaier I; Philippe T; Picci P; Ranchere D; Renne SL; Sbaraglia M; Thway K; Wagrodzki M; Wang WL; Yoshida A; Mariani L; Kawai A; Stacchiotti S
JAMA Oncol; 2018 Sep; 4(9):e180219. PubMed ID: 29800950
[TBL] [Abstract][Full Text] [Related]
3. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
[TBL] [Abstract][Full Text] [Related]
5. Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.
Testa S; Bui NQ; Ganjoo KN
Cancer Res Commun; 2023 Jul; 3(7):1212-1223. PubMed ID: 37448552
[TBL] [Abstract][Full Text] [Related]
6. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
7. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
8. Medical treatment of advanced malignant perivascular epithelioid cell tumors.
Fabbroni C; Sbaraglia M; Sanfilippo R
Curr Opin Oncol; 2020 Jul; 32(4):301-306. PubMed ID: 32541317
[TBL] [Abstract][Full Text] [Related]
9. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
[TBL] [Abstract][Full Text] [Related]
10. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Gounder MM; Merriam P; Ratan R; Patel SR; Chugh R; Villalobos VM; Thornton M; Van Tine BA; Abdelhamid AH; Whalen J; Yang J; Rajarethinam A; Duh MS; Bobbili PJ; Huynh L; Totev TI; Lax AK; Agarwal S; Demetri GD
Cancer; 2021 Apr; 127(8):1311-1317. PubMed ID: 33296083
[TBL] [Abstract][Full Text] [Related]
13. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
14. Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).
Machado I; Cruz J; Lavernia J; Rayon JM; Poveda A; Llombart-Bosch A
Int J Surg Pathol; 2017 Sep; 25(6):543-549. PubMed ID: 28459168
[TBL] [Abstract][Full Text] [Related]
15. Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.
Levin G; Capella MP; Meyer R; Brezinov Y; Gotlieb WH
Arch Gynecol Obstet; 2024 Jun; 309(6):2381-2386. PubMed ID: 38664269
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Matsumoto K; Onda T; Yaegashi N
Jpn J Clin Oncol; 2015 May; 45(5):408-10. PubMed ID: 25765457
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?
Martin-Liberal J; Tirado OM; García del Muro X
Expert Rev Anticancer Ther; 2015 Mar; 15(3):257-9. PubMed ID: 25586480
[TBL] [Abstract][Full Text] [Related]
20. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Joka M; Boeck S; Zech CJ; Seufferlein T; Wichert Gv; Licht T; Krause A; Jauch KW; Heinemann V; Bruns CJ
Anticancer Drugs; 2014 Oct; 25(9):1095-101. PubMed ID: 25029236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
